Jaime Sanz at Universitat de Valencia Facultad de Medicina - Research Interests, Publications & Academic Profile

Jaime Sanz

Profesor asociado asistencial

Universidad Católica de Valencia Facultad de Medicina

Spain

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Korean students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Immunology

80%

Virology

40%

Hematology

100%

Graft-versus-host Disease

90%

Cancer Therapy

80%

Stem Cell Transplantation

80%

Transplantation

70%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles20

Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy

Article Link

Year:

2024

Haploidentical stem cell donor choice for patients with acute myeloid leukemia: a study from the ALWP of the EBMT.

Article Link

Year:

2024

Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination for graft-versus-host disease prevention in haploidentical transplantation for adult acute myeloid leukemia: A report from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party

Article Link

Year:

2024

Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT

Article Link

Year:

2024

Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study

Article Link

Year:

2024

Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies

Article Link

Year:

2024

Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial

Article Link

Year:

2024

Outcome of Human Parainfluenza Virus infection in allogeneic stem cell transplantation recipients: possible impact of ribavirin therapy

Article Link

Year:

2024

Post-Transplantation Cyclophosphamide-Based Graft-versusHost Disease Prophylaxis in HLA-Matched and Haploidentical Donor Transplantation for Patients with Hodgkin Lymphoma: A Comparative Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Article Link

Year:

2024

Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Article Link

Year:

2024

Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials

Article Link

Year:

2023

Long-term outcome of second allogeneic hematopoietic stem cell transplantation (HSCT2) for primary graft failure in patients with acute leukemia in remission: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Article Link

Year:

2023

Extracorporeal Photopheresis in Graft-versus-Host Disease

Article Link

Year:

2023

Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

Article Link

Year:

2023

Outcomes of graft failure after umbilical cord blood transplantation in acute leukemia: a study from Eurocord and the Acute Leukemia Working Party of the EBMT

Article Link

Year:

2023

Post‐transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA‐mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT

Article Link

Year:

2023

Post-transplant cyclophosphamide in acute leukemia patients receiving more than 5/10 HLA-mismatched allogeneic hematopoietic cell transplantation from related donors: A study on behalf of the ALWP of the EBMT

Article Link

Year:

2023

Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT

Article Link

Year:

2023

Outcomes of subsequent neoplasms after umbilical cord blood transplantation in Europe

Article Link

Year:

2023

Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma

Article Link

Year:

2023

Collaborators6

William Ying Khee Hwang

Professor and Chair

Duke-NUS Medical School

SINGAPORE

Per Ljungman

Karolinska University Hospital

SWEDEN

Suhag Parikh

Emory University

UNITED STATES

Didier Blaise

Professor of Medicine

Aix-Marseille University

FRANCE

Thomas Pabst

SWITZERLAND

Jurgen Kuball

UMC Utrecht

NETHERLANDS

How do Korean students reach out?

Meet Kite AI